What changed
What changedКомпанія Intuitive Surgical розширює раду директорів з десяти до одинадцяти осіб та призначає Аарона Мартіна незалежним директором з 1 січня 2027 року. Це кадрове рішення змінює структуру управління та супроводжується стандартним пакетом винагороди для нового члена ради.

What changedIntuitive Surgical's revenue for the third quarter of 2026 was $3,049 million, up 21.7% from a year earlier. Operating income fell 22%, to $593 million, and net income fell 25.8%.

Deals & ownershipIn September 2026, two Intuitive Surgical executives sold shares under Rule 10b5‑1 plans. Mark Brosius, executive vice president and chief manufacturing and supply chain officer, sold 48 shares for $17,140.93 on September 10‑11. Fredrik Widman, vice president, corporate controller, sold 1,089 shares for $407,765.16 on September 15.

Company history
October 2026
INTUITIVE SURGICAL INC: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,162,400,000 USD (2.2 billion; 2,162 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,061,200,000 USD (2.1 billion; 2,061 million); change +4.9% Source
- 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 408,300,000 USD (408 million); same period a year earlier (2025-07-01 to 2025-09-30): 329,400,000 USD (329 million); change +24% Source
- 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 1,140,800,000 USD (1.1 billion; 1,141 million); same period a year earlier (2025-01-01 to 2025-09-30): 958,900,000 USD (959 million); change +19% Source
- 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 3,197,000,000 USD (3.2 billion; 3,197 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,138,000,000 USD (2.1 billion; 2,138 million); change +49.5% Source
- 2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 2,978,100,000 USD (3 billion; 2,978 million); previous balance (2025-12-31): 3,368,000,000 USD (3.4 billion; 3,368 million); change -11.6% Source
- 2026-10-21: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 15,986,200,000 USD (16 billion; 15,986 million); previous balance (2025-12-31): 17,824,000,000 USD (17.8 billion; 17,824 million); change -10.3% Source
- 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 3,048,700,000 USD (3 billion; 3,049 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,505,100,000 USD (2.5 billion; 2,505 million); change +21.7% Source
- 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 8,711,800,000 USD (8.7 billion; 8,712 million); same period a year earlier (2025-01-01 to 2025-09-30): 7,198,500,000 USD (7.2 billion; 7,199 million); change +21% Source
- 2026-10-21: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 2,084,300,000 USD (2.1 billion; 2,084 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,662,400,000 USD (1.7 billion; 1,662 million); change +25.4% Source
- 2026-10-21: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 5,875,200,000 USD (5.9 billion; 5,875 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,738,000,000 USD (4.7 billion; 4,738 million); change +24% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 592,600,000 USD (593 million); same period a year earlier (2025-07-01 to 2025-09-30): 759,700,000 USD (760 million); change -22% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,419,800,000 USD (2.4 billion; 2,420 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,081,200,000 USD (2.1 billion; 2,081 million); change +16.3% Source
September 2026
INTUITIVE SURGICAL INC: 3 recorded developments from 3 official sources in 2026-09.
- Summary: S (open market or private sale): 2 transaction(s) on 2026-09-10 to 2026-09-11, 48 disposed, total value 17,140.93 USD at a weighted average price of 357.1027 USD; owned after the last one: 764 Source
- 2026-09-15: Units to be sold: 2178; aggregate market value: 823153.32 USD; units outstanding: 353278038 Source
- 2026-09-16: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-15, 1,089 disposed, total value 407,765.16 USD at a weighted average price of 374.44 USD; owned after the last one: 1,026 Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| November 2, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 10, 2026 | Gary Loeb | Sale 10b5-1 plan notice filed | 400 | $458.15 | $183,260 | SEC |
| November 4, 2026 | Gary S Guthart | Sale 10b5-1 plan | 10,000 | $457.34 | $4,573,370 | SEC |
| November 4, 2026 | Craig H Barratt | Sale 10b5-1 plan notice filed | 1,150 | $460.00 | $529,003 | SEC |
| October 30, 2026 | Fredrik Widman | Sale 10b5-1 plan | 5,448 | $436.06 | $2,375,628 | SEC |
| October 30, 2026 | Fredrik Widman | Planned sale 10b5-1 plan | 4,359 | — | $1,956,145 | SEC |
| October 30, 2026 | Mark Brosius | Sale 10b5-1 plan | 124 | $450.77 | $55,896 | SEC |
| October 28, 2026 | Mark Brosius | Sale 10b5-1 plan | 183 | $448.33 | $82,044 | SEC |
| October 23, 2026 | Guthart Family Trust | Planned sale 10b5-1 plan | 27,139 | — | $12,045,645 | SEC |
| October 23, 2026 | Gary S Guthart | Sale 10b5-1 plan | 20,095 | $451.61 | $9,075,137 | SEC |
| October 23, 2026 | Fredrik Widman | Sale 10b5-1 plan notice filed | 4,047 | $453.21 | $1,834,124 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 29,561,783 | $12,020,707,694 | -1.5% | Q3 2026 |
| State Street | 16,173,422 | $6,576,598,588 | +0.7% | Q3 2026 |
| Geode Capital Management | 8,542,334 | $3,458,144,928 | +0.1% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 4,954,874 | $1,970,454,292 | — | Q2 2026 |
| Wellington Management | 3,352,466 | $1,363,213,250 | -11.8% | Q3 2026 |
| Fidelity (FMR) | 2,310,391 | $939,474,527 | -45.7% | Q3 2026 |
| Capital Research Global Investors | 2,208,824 | $898,174,103 | +42.4% | Q3 2026 |
| Citadel Advisors | 1,370,412 | $557,250,632 | +191.5% | Q3 2026 |
| Renaissance Technologies | 456,411 | $185,590,405 | -9.5% | Q3 2026 |
| Two Sigma Investments | 407,249 | $165,599,661 | -79.4% | Q3 2026 |
| ARK Investment Management (Cathie Wood) | 74,399 | $30,252,865 | +5.7% | Q3 2026 |
| Millennium Management | 13,020 | $5,294,323 | -96.9% | Q3 2026 |
| D. E. Shaw & Co. | 12,847 | $5,223,976 | -96.2% | Q3 2026 |
| Bridgewater Associates | 11,560 | $4,700,643 | -40.2% | Q3 2026 |
| T. Rowe Price | 9,945,424 | $4,044,108 | -11.6% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.